Associate Professor Jagat Kanwar, Group Leader “Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research” working in Deakin University, Australia. He did his PhD in 1993 from PGIMER, Chandigarh, India and worked as a Senior Scientist in The Auckland University, New Zealand for more than 10 years. He has a national and international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. His research is also focused on miRNA, aptamer, locked nucleic acid (LNA) LNA-modified chimeric aptamers-siRNA conjugates, and immunoliposomes technology and disease targeted drug discovery. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. He designed nanocarriers for applications in vaccines, immunotherapy, and drug delivery of antigens immunostimulatory ligands to dendritic cells and subsequent stimuli to T- lymphocytes, B-lymphocytes and TH17 cells.   Associate Professor Jagat Kanwar, Group Leader “Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research” working in Deakin University, Australia. He did his PhD in 1993 from PGIMER, Chandigarh, India and worked as a Senior Scientist in The Auckland University, New Zealand for more than 10 years. He has a national and international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. His research is also focused on miRNA, aptamer, locked nucleic acid (LNA) LNA-modified chimeric aptamers-siRNA conjugates, and immunoliposomes technology and disease targeted drug discovery. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. He designed nanocarriers for applications in vaccines, immunotherapy, and drug delivery of antigens immunostimulatory ligands to dendritic cells and subsequent stimuli to T- lymphocytes, B-lymphocytes and TH17 cells.